BIOMAT Database Logo BIOMAT Database Logo

Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study. 1997

L S Eriksson, and R Olsson, and H Glauman, and H Prytz, and R Befrits, and B O Rydén, and K Einarsson, and S Lindgren, and S Wallerstedt, and M Wedén
Dept. of Medicine, Huddinge Hospital, Sweden.

BACKGROUND Ursodeoxycholic acid (UDCA) has been shown to improve serum levels of liver enzymes and bilirubin in primary biliary cirrhosis (PBC). However, it is still uncertain whether UDCA treatment also improves symptoms, liver histology, and survival without liver transplantation. METHODS We randomized 116 patients with PBC to receive 0.5 g UDCA (n = 60) or placebo (n = 56) daily for 2 years. During the next 2 years, 80% of the UDCA-treated patients and 65% of the placebo-treated patients continued to take UDCA. RESULTS UDCA improved serum enzyme values but not survival, symptoms, serum bilirubin levels, or liver histology. There was no significant difference in response between initially symptomatic and asymptomatic patients. CONCLUSIONS UDCA in a dosage of 7.7 mg/kg body weight is of little benefit in PBC. This does not exclude the possibility that larger doses have beneficial effects.

UI MeSH Term Description Entries
D008105 Liver Cirrhosis, Biliary FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cholangitis involves the destruction of small intra-hepatic bile ducts and decreased bile secretion. Secondary biliary cholangitis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes. Biliary Cirrhosis,Biliary Cirrhosis, Primary,Biliary Cirrhosis, Secondary,Cholangitis, Chronic Nonsuppurative Destructive,Liver Cirrhosis, Obstructive,Primary Biliary Cholangitis,Biliary Cirrhosis, Primary, 1,Primary Biliary Cirrhosis,Secondary Biliary Cholangitis,Secondary Biliary Cirrhosis,Biliary Cholangitides, Primary,Biliary Cholangitis, Primary,Biliary Cholangitis, Secondary,Cholangitides, Primary Biliary,Cholangitis, Primary Biliary,Cholangitis, Secondary Biliary,Cirrhosis, Biliary,Cirrhosis, Secondary Biliary,Liver Cirrhoses, Biliary,Obstructive Liver Cirrhosis,Primary Biliary Cholangitides,Secondary Biliary Cholangitides
D008111 Liver Function Tests Blood tests that are used to evaluate how well a patient's liver is working and also to help diagnose liver conditions. Function Test, Liver,Function Tests, Liver,Liver Function Test,Test, Liver Function,Tests, Liver Function
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001774 Blood Chemical Analysis An examination of chemicals in the blood. Analysis, Blood Chemical,Chemical Analysis, Blood,Analyses, Blood Chemical,Blood Chemical Analyses,Chemical Analyses, Blood
D002756 Cholagogues and Choleretics Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic). Choleretics,Cholagogues,Cholagogues, Choleretics,Choleretics and Cholagogues,Hydrocholeretics
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

L S Eriksson, and R Olsson, and H Glauman, and H Prytz, and R Befrits, and B O Rydén, and K Einarsson, and S Lindgren, and S Wallerstedt, and M Wedén
A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis.
September 1995, Hepatology (Baltimore, Md.),
L S Eriksson, and R Olsson, and H Glauman, and H Prytz, and R Befrits, and B O Rydén, and K Einarsson, and S Lindgren, and S Wallerstedt, and M Wedén
The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.
May 1994, Hepatology (Baltimore, Md.),
L S Eriksson, and R Olsson, and H Glauman, and H Prytz, and R Befrits, and B O Rydén, and K Einarsson, and S Lindgren, and S Wallerstedt, and M Wedén
Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial.
November 1989, Gastroenterology,
L S Eriksson, and R Olsson, and H Glauman, and H Prytz, and R Befrits, and B O Rydén, and K Einarsson, and S Lindgren, and S Wallerstedt, and M Wedén
[Combined ursodeoxycholic acid plus colchicine--treatment of primary biliary cirrhosis: results of a placebo-controlled double-blind study].
March 1992, Zeitschrift fur Gastroenterologie,
L S Eriksson, and R Olsson, and H Glauman, and H Prytz, and R Befrits, and B O Rydén, and K Einarsson, and S Lindgren, and S Wallerstedt, and M Wedén
A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis.
December 1990, Gastroenterologia Japonica,
L S Eriksson, and R Olsson, and H Glauman, and H Prytz, and R Befrits, and B O Rydén, and K Einarsson, and S Lindgren, and S Wallerstedt, and M Wedén
Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group.
July 1990, Journal of hepatology,
L S Eriksson, and R Olsson, and H Glauman, and H Prytz, and R Befrits, and B O Rydén, and K Einarsson, and S Lindgren, and S Wallerstedt, and M Wedén
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up.
January 1993, Journal of gastroenterology and hepatology,
L S Eriksson, and R Olsson, and H Glauman, and H Prytz, and R Befrits, and B O Rydén, and K Einarsson, and S Lindgren, and S Wallerstedt, and M Wedén
Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis.
December 2000, Alimentary pharmacology & therapeutics,
L S Eriksson, and R Olsson, and H Glauman, and H Prytz, and R Befrits, and B O Rydén, and K Einarsson, and S Lindgren, and S Wallerstedt, and M Wedén
Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients.
September 2001, Alimentary pharmacology & therapeutics,
L S Eriksson, and R Olsson, and H Glauman, and H Prytz, and R Befrits, and B O Rydén, and K Einarsson, and S Lindgren, and S Wallerstedt, and M Wedén
[Treatment of primary biliary cirrhosis with ursodeoxycholic acid].
January 2000, Vutreshni bolesti,
Copied contents to your clipboard!